Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 2/20 | 0.62 |
| ▸ | ALK | Q9UM73 | 13/20 | 0.54 |
| ▸ | INSR | P06213 | 9/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.53 |
| ▸ | ULK1 | O75385 | 1/20 | 0.53 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.53 |
| ▸ | MET | P08581 | 3/20 | 0.52 |
| ▸ | CDC7 | O00311 | 1/20 | 0.51 |
| ▸ | PLK4 | O00444 | 1/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.51 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
| ▸ | PAK4 | O96013 | 1/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1460618 | 0.92 | MAPK3 (0.61) | MAPK3ALKINSR | |
| SCHEMBL1460540 | 0.91 | MAPK3 (0.63) | MAPK3ALKPTK2METEGFR | |
| SCHEMBL10011852 | 0.91 | MAPK3 (0.59) | MAPK3ALKINSRAURKALRRK2 | |
| SCHEMBL601332 | 0.88 | ULK1 (0.52) | MAPK3ALKPTK2ULK1MET | |
| SCHEMBL10292068 | 0.86 | MAPK3 (0.61) | MAPK3ALKINSRMETEGFR | |
| SCHEMBL1460878 | 0.83 | MAPK3 (0.62) | MAPK3ALKINSRMETEGFR | |
| SCHEMBL1459614 | 0.83 | LRRK2 (0.55) | ALKINSRMETEGFRLRRK2 | |
| SCHEMBL10011055 | 0.82 | EGFR (0.61) | MAPK3ALKINSRMETEGFR | |
| SCHEMBL4089313 | 0.82 | ALK (0.59) | MAPK3ALKINSR | |
| SCHEMBL1459625 | 0.82 | EGFR (0.67) | MAPK3PTK2METEGFRLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475648-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-07-18 | — | — | EP | claimed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | claimed |
| WO-2011029807-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-03-17 | — | — | WO | claimed |
| EP-2475648-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-07-18 | — | — | EP | disclosed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| WO-2011029807-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011029807-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | JAK3, JAK1, JAK2 | MAPK3 45/4885ALK 545/4885INSR 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.